RESUMEN
Arthrogryposis multiplex congenita (AMC) is characterized by heterogeneous nonprogressive multiple joint contractures appearing at birth. We present a consanguineous Israeli-Druze family with several members presenting with AMC. A variable intra-familial phenotype and pected autosomal recessive inheritance prompted molecular diagnosis by whole-exome sequencing. Variant analysis focused on rare homozygous changes, revealed a missense variant in MYBPC1, NM_002465:c.556G>A (p.E286K), affecting the last nucleotide of Exon 8. This novel variant was not observed in the common variant databases and co-segregated as expected within the extended family. MYBPC1 encodes a slow skeletal muscle isoform, essential for muscle contraction. Heterozygous mutations in this gene are associated with distal arthrogryposis types 1b and 2, whereas a homozygous nonsense mutation is implicated in one family with lethal congenital contractural syndrome 4. We present a novel milder MYBPC1 homozygous phenotype.
Asunto(s)
Artrogriposis/genética , Proteínas Portadoras/genética , Estudios de Asociación Genética , Homocigoto , Mutación Missense , Artrogriposis/diagnóstico , Artrogriposis/etnología , Artrogriposis/patología , Secuencia de Bases , Proteínas Portadoras/metabolismo , Preescolar , Consanguinidad , Etnicidad , Exoma , Exones , Femenino , Expresión Génica , Genotipo , Humanos , Lactante , Israel , Masculino , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Linaje , FenotipoRESUMEN
The mitochondrial deoxyribonucleotide (dNTP) pool is separated from the cytosolic pool because the mitochondria inner membrane is impermeable to charged molecules. The mitochondrial pool is maintained by either import of cytosolic dNTPs through dedicated transporters or by salvaging deoxynucleosides within the mitochondria; apparently, enzymes of the de novo dNTP synthesis pathway are not present in the mitochondria. In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on the mitochondrial salvage pathway enzymes, the deoxyribonucleosides kinases. Two of the four human deoxyribonucleoside kinases, deoxyguanosine kinase (dGK) and thymidine kinase-2 (TK2), are expressed in mitochondria. Human dGK efficiently phosphorylates deoxyguanosine and deoxyadenosine, whereas TK2 phosphorylates deoxythymidine, deoxycytidine and deoxyuridine. Here we identify two mutations in TK2, histidine 90 to asparagine and isoleucine 181 to asparagine, in four individuals who developed devastating myopathy and depletion of muscular mitochondrial DNA in infancy. In these individuals, the activity of TK2 in muscle mitochondria is reduced to 14-45% of the mean value in healthy control individuals. Mutations in TK2 represent a new etiology for mitochondrial DNA depletion, underscoring the importance of the mitochondrial dNTP pool in the pathogenesis of mitochondrial depletion.
Asunto(s)
ADN Mitocondrial/metabolismo , Mitocondrias Musculares/enzimología , Miopatías Mitocondriales/genética , Mutación Puntual/genética , Timidina Quinasa/genética , Secuencia de Bases , Preescolar , Análisis Mutacional de ADN , ADN Mitocondrial/genética , Femenino , Humanos , Lactante , Masculino , Mitocondrias Musculares/genética , Mitocondrias Musculares/patología , Miopatías Mitocondriales/enzimología , Miopatías Mitocondriales/patología , Miopatías Mitocondriales/fisiopatología , Datos de Secuencia Molecular , Fosfotransferasas (Aceptor de Grupo Alcohol)/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Timidina Quinasa/metabolismoRESUMEN
Mitochondrial DNA (mtDNA)-depletion syndromes (MDS; OMIM 251880) are phenotypically heterogeneous, autosomal-recessive disorders characterized by tissue-specific reduction in mtDNA copy number. Affected individuals with the hepatocerebral form of MDS have early progressive liver failure and neurological abnormalities, hypoglycemia and increased lactate in body fluids. Affected tissues show both decreased activity of the mtDNA-encoded respiratory chain complexes (I, III, IV, V) and mtDNA depletion. We used homozygosity mapping in three kindreds of Druze origin to map the gene causing hepatocerebral MDS to a region of 6.1 cM on chromosome 2p13, between markers D2S291 and D2S2116. This interval encompasses the gene (DGUOK) encoding the mitochondrial deoxyguanosine kinase (dGK). We identified a single-nucleotide deletion (204delA) within the coding region of DGUOK that segregates with the disease in the three kindreds studied. Western-blot analysis did not detect dGK protein in the liver of affected individuals. The main supply of deoxyribonucleotides (dNTPs) for mtDNA synthesis comes from the salvage pathway initiated by dGK and thymidine kinase-2 (TK2). The association of mtDNA depletion with mutated DGUOK suggests that the salvage-pathway enzymes are involved in the maintenance of balanced mitochondrial dNTP pools.
Asunto(s)
ADN Mitocondrial/metabolismo , Hepatocitos/metabolismo , Enfermedades Mitocondriales/enzimología , Enfermedades Mitocondriales/genética , Fosfotransferasas (Aceptor de Grupo Alcohol)/genética , Mutación Puntual/genética , Telencéfalo/metabolismo , Secuencia de Bases , Southern Blotting , Western Blotting , Mapeo Cromosómico , Cromosomas Humanos Par 2/genética , Consanguinidad , Análisis Mutacional de ADN , ADN Mitocondrial/genética , Femenino , Expresión Génica , Homocigoto , Humanos , Masculino , Enfermedades Mitocondriales/metabolismo , Datos de Secuencia Molecular , Linaje , Alineación de SecuenciaRESUMEN
All molybdoenzymes other than nitrogenase require molybdopterin as a metal-binding cofactor. Several genes necessary for the synthesis of the molybdenum cofactor (MoCo) have been characterized in bacteria and plants. The proteins encoded by the Escherichia coli genes moaA and moaC catalyse the first steps in MoCo synthesis. The human homologues of these genes are therefore candidate genes for molybdenum cofactor deficiency, a rare and fatal disease. Using oligonucleotides complementary to a conserved region in the moaA gene, we have isolated a human cDNA derived from liver mRNA. This transcript contains an open reading frame (ORF) encoding the human moaA homologue and a second ORF encoding a human moaC homologue. Mutations can be found in the majority of MoCo-deficient patients that confirm the functional role of both ORFs in the corresponding gene MOCS1 (for 'molybdenum cofactor synthesis-step 1'). Northern-blot analysis detected only full-length transcripts containing both consecutive ORFs in various human tissues. The mRNA structure suggests a translation reinitiation mechanism for the second ORF. These data indicate the existence of a eukaryotic mRNA, which as a single and uniform transcript guides the synthesis of two different enzymatic polypeptides with disease-causing potential.
Asunto(s)
Coenzimas , Errores Innatos del Metabolismo/genética , Metaloproteínas/metabolismo , Mutación , Proteínas Nucleares/genética , Pteridinas/metabolismo , Secuencia de Aminoácidos , Secuencia de Bases , Liasas de Carbono-Carbono , Secuencia Conservada , Femenino , Humanos , Masculino , Datos de Secuencia Molecular , Cofactores de Molibdeno , Proteínas Nucleares/metabolismo , Sistemas de Lectura Abierta , Linaje , ARN Mensajero , Alineación de Secuencia , Homología de Secuencia de AminoácidoRESUMEN
Thiamine-responsive megaloblastic anaemia (TRMA), also known as Rogers syndrome, is an early onset, autosomal recessive disorder defined by the occurrence of megaloblastic anaemia, diabetes mellitus and sensorineural deafness, responding in varying degrees to thiamine treatment (MIM 249270). We have previously narrowed the TRMA locus from a 16-cM to a 4-cM interval on chromosomal region 1q23.3 (refs 3,4) and this region has been further refined to a 1.4-cM interval. Previous studies have suggested that deficiency in a high-affinity thiamine transporter may cause this disorder. Here we identify the TRMA gene by positional cloning. We assembled a P1-derived artificial chromosome (PAC) contig spanning the TRMA candidate region. This clarified the order of genetic markers across the TRMA locus, provided 9 new polymorphic markers and narrowed the locus to an approximately 400-kb region. Mutations in a new gene, SLC19A2, encoding a putative transmembrane protein homologous to the reduced folate carrier proteins, were found in all affected individuals in six TRMA families, suggesting that a defective thiamine transporter protein (THTR-1) may underlie the TRMA syndrome.
Asunto(s)
Anemia Megaloblástica/genética , Sordera/genética , Diabetes Mellitus/genética , Proteínas de Transporte de Membrana , Mutación , Secuencia de Aminoácidos , Anemia Megaloblástica/complicaciones , Anemia Megaloblástica/tratamiento farmacológico , Animales , Secuencia de Bases , Proteínas Portadoras/genética , Cricetinae , ADN/genética , Cartilla de ADN/genética , Sordera/complicaciones , Complicaciones de la Diabetes , Femenino , Genes Recesivos , Marcadores Genéticos , Humanos , Masculino , Ratones , Datos de Secuencia Molecular , Mapeo Físico de Cromosoma , Homología de Secuencia de Aminoácido , Síndrome , Tiamina/metabolismo , Tiamina/uso terapéuticoRESUMEN
Very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency is an inborn mitochondrial fatty-acid beta-oxidation (FAO) defect associated with a broad mutational spectrum, with phenotypes ranging from fatal cardiopathy in infancy to adolescent-onset myopathy, and for which there is no established treatment. Recent data suggest that bezafibrate could improve the FAO capacities in beta-oxidation-deficient cells, by enhancing the residual level of mutant enzyme activity via gene-expression stimulation. Since VLCAD-deficient patients frequently harbor missense mutations with unpredictable effects on enzyme activity, we investigated the response to bezafibrate as a function of genotype in 33 VLCAD-deficient fibroblasts representing 45 different mutations. Treatment with bezafibrate (400 microM for 48 h) resulted in a marked increase in FAO capacities, often leading to restoration of normal values, for 21 genotypes that mainly corresponded to patients with the myopathic phenotype. In contrast, bezafibrate induced no changes in FAO for 11 genotypes corresponding to severe neonatal or infantile phenotypes. This pattern of response was not due to differential inductions of VLCAD messenger RNA, as shown by quantitative real-time polymerase chain reaction, but reflected variable increases in measured VLCAD residual enzyme activity in response to bezafibrate. Genotype cross-analysis allowed the identification of alleles carrying missense mutations, which could account for these different pharmacological profiles and, on this basis, led to the characterization of 9 mild and 11 severe missense mutations. Altogether, the responses to bezafibrate reflected the severity of the metabolic blockage in various genotypes, which appeared to be correlated with the phenotype, thus providing a new approach for analysis of genetic heterogeneity. Finally, this study emphasizes the potential of bezafibrate, a widely prescribed hypolipidemic drug, for the correction of VLCAD deficiency and exemplifies the integration of molecular information in a therapeutic strategy.
Asunto(s)
Acil-CoA Deshidrogenasa de Cadena Larga/deficiencia , Acil-CoA Deshidrogenasa de Cadena Larga/genética , Bezafibrato/uso terapéutico , Hipolipemiantes/uso terapéutico , Errores Innatos del Metabolismo Lipídico/genética , Acil-CoA Deshidrogenasa de Cadena Larga/química , Acil-CoA Deshidrogenasa de Cadena Larga/metabolismo , Animales , Células Cultivadas , Ácidos Grasos/metabolismo , Fibroblastos/citología , Fibroblastos/efectos de los fármacos , Fibroblastos/enzimología , Fibroblastos/patología , Terapia Genética/métodos , Genotipo , Humanos , Errores Innatos del Metabolismo Lipídico/enzimología , Modelos Moleculares , Reacción en Cadena de la Polimerasa , ARN Mensajero/genética , Ratas , Piel/citología , Piel/enzimología , Piel/patologíaRESUMEN
BACKGROUND: Infection and dehiscence of simple lacerations is common in horses, and consistently effective methods of prevention are yet to be found. Honey has been shown to promote wound healing when applied topically; however, intralesional application prior to wound closure has not been reported. OBJECTIVES: To examine whether intralesional application of medical grade honey (MGH) would reduce the incidence of infection and dehiscence following wound closure. STUDY DESIGN: Prospective, open-label randomised block design clinical study. METHODS: Lacerations, treated by field practitioners, were divided into treatment and control groups using block randomisation. Horses in the treatment group received a single intralesional treatment with l-mesitran gel (MGH). Data were collected at the time of wound closure and at suture removal. RESULTS: Data from 127 horses were included, 69 MGH-treated and 58 control cases. No adverse effects of the MGH were recorded. MGH-treated horses were more likely to completely heal (P = 0.006, odds ratio [OR] 3.40 95% confidence interval [CI] 1.41-8.20), to have no signs of infection (P = 0.007, OR 3.64, CI 1.42-9.26) and for the veterinarians to report some degree of satisfaction (P = 0.04, OR 2.72, CI 1.05-7.09) compared to control cases. Numbers needed to treat for complete healing was 5.1 (CI 2.8-40). MAIN LIMITATIONS: Clinical studies have inherent flaws compared to wound healing models, because of variability between wounds. There were more horses with limb injuries in the control group, although not statistically significant, this may have biased the results. Clinical satisfaction and signs of infection were subjective evaluations and evaluators were not blinded to the treatment group. CONCLUSIONS: Intralesional application of MGH to lacerations prior to wound closure may be beneficial in preventing infection and dehiscence. Larger, blinded studies focusing on wounds at a specific location with more objective assessment should be pursued.
Asunto(s)
Infecciones Bacterianas/veterinaria , Miel , Enfermedades de los Caballos/prevención & control , Laceraciones/veterinaria , Cicatrización de Heridas , Animales , Infecciones Bacterianas/prevención & control , Femenino , Caballos , MasculinoRESUMEN
Because of the prospect of a serious decline in the nation's biomedical research capacity owing to diminished federal appropriations, temporary measures should be initiated promptly by the National Institutes of Health to preserve the stability of resources and diversity of research required for future productivity. It is recommended that the available funds be distributed in such a way as to permit some support for 50 percent of competing grant applications approved by the National Institutes of Health study sections. Measures proposed for consideration are a sliding scale for funding, a greater across-the-board reduction, a limit on support for an individual laboratory, and a review of indirect costs.
Asunto(s)
National Institutes of Health (U.S.) , Apoyo a la Investigación como Asunto , National Institutes of Health (U.S.)/organización & administración , Apoyo a la Investigación como Asunto/economía , Estados UnidosRESUMEN
Pompe disease is an autosomal recessive disorder of glycogen metabolism caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). It presents at any age, with variable rates of progression ranging from a rapidly progressive course, often fatal by one-year of age, to a more slowly, but nevertheless relentlessly progressive course, resulting in significant morbidity and premature mortality. In infants, early initiation of enzyme replacement therapy is needed to gain the maximum therapeutic benefit, underscoring the need for early diagnosis. Several new methods for measuring GAA activity have been developed. The Pompe Disease Diagnostic Working Group met to review data generated using the new methods, and to establish a consensus regarding the application of the methods for the laboratory diagnosis of Pompe disease. Skin fibroblasts and muscle biopsy have traditionally been the samples of choice for measuring GAA activity. However, new methods using blood samples are rapidly becoming adopted because of their speed and convenience. Measuring GAA activity in blood samples should be performed under acidic conditions (pH 3.8-4.0), using up to 2 mM of the synthetic substrate 4-methylumbelliferyl-alpha-D-glucoside or glycogen (50 mg/mL), in the presence of acarbose (3-9 microM) to inhibit the isoenzyme maltase-glucoamylase. The activity of a reference enzyme should also be measured to confirm the quality of the sample. A second test should be done to support the diagnosis of Pompe disease until a program for external quality assurance and proficiency testing of the enzymatic diagnosis in blood is established.
Asunto(s)
Glucano 1,4-alfa-Glucosidasa/sangre , Enfermedad del Almacenamiento de Glucógeno Tipo II/diagnóstico , Técnicas de Laboratorio Clínico , Humanos , LactanteRESUMEN
Despite great advances in health-related research and health care, major challenges remain regarding the causes and cures of many diseases; these may be overcome with further research. Our society is enthusiastic about fostering such investigations. However, available federal funds limit many such projects. Previously there have been sizable increases in the NIH budget, but because of the escalating cost of scientific investigation and the pressures of financing other much-needed governmental programs, recent growth in biomedical research funding has barely kept up with inflation. This article focuses on select attempts to sustain the record of scientific achievement enabled in the past by continued increasing investment and also suggests some solutions.
Asunto(s)
Investigación Biomédica/economía , Financiación Gubernamental , National Institutes of Health (U.S.)/economía , Apoyo a la Investigación como Asunto , Presupuestos , Humanos , Revisión por Pares , Estados UnidosRESUMEN
Mitochondrial fatty acid beta-oxidation is important for energy production, which is stressed by the different defects found in this pathway. Most of the enzyme deficiencies causing these defects are well characterized at both the protein and genomic levels. One exception is carnitine palmitoyltransferase I (CPT I) deficiency, of which until now no mutations have been reported although the defect is enzymatically well characterized. CPT I is the key enzyme in the carnitine-dependent transport across the mitochondrial inner membrane and its deficiency results in a decreased rate of fatty acid beta-oxidation. Here we report the first delineation of the molecular basis of hepatic CPT I deficiency in a new case. cDNA analysis revealed that this patient was homozygous for a missense mutation (D454G). The effect of the identified mutation was investigated by heterologous expression in yeast. The expressed mutant CPT IA displayed only 2% of the activity of the expressed wild-type CPT IA, indicating that the D454G mutation is the disease-causing mutation. Furthermore, in patient's fibroblasts the CPT IA protein was markedly reduced on immunoblot, suggesting that the mutation renders the protein unstable.
Asunto(s)
Carnitina O-Palmitoiltransferasa/deficiencia , Isoenzimas/deficiencia , Errores Innatos del Metabolismo Lipídico/genética , Secuencia de Aminoácidos , Transporte Biológico , Carnitina O-Palmitoiltransferasa/genética , Carnitina O-Palmitoiltransferasa/fisiología , Consanguinidad , Secuencia de Consenso , Ácidos Dicarboxílicos/orina , Ácidos Grasos/metabolismo , Femenino , Humanos , Hipoglucemia/etiología , Lactante , Isoenzimas/genética , Isoenzimas/fisiología , Errores Innatos del Metabolismo Lipídico/enzimología , Errores Innatos del Metabolismo Lipídico/orina , Hígado/enzimología , Mitocondrias/metabolismo , Datos de Secuencia Molecular , Alineación de Secuencia , Homología de Secuencia de Aminoácido , Especificidad de la EspecieRESUMEN
Mucolipidosis IIIC, or variant pseudo-Hurler polydystrophy, is an autosomal recessive disease of lysosomal hydrolase trafficking. Unlike the related diseases, mucolipidosis II and IIIA, the enzyme affected in mucolipidosis IIIC (N-Acetylglucosamine-1-phosphotransferase [GlcNAc-phosphotransferase]) retains full transferase activity on synthetic substrates but lacks activity on lysosomal hydrolases. Bovine GlcNAc-phosphotransferase has recently been isolated as a multisubunit enzyme with the subunit structure alpha(2)beta(2)gamma(2). We cloned the cDNA for the human gamma-subunit and localized its gene to chromosome 16p. We also showed, in a large multiplex Druze family that exhibits this disorder, that MLIIIC also maps to this chromosomal region. Sequence analysis of the gamma-subunit cDNA in patients from 3 families identified a frameshift mutation, in codon 167 of the gamma subunit, that segregated with the disease, indicating MLIIIC results from mutations in the phosphotransferase gamma-subunit gene. This is to our knowledge the first description of the molecular basis for a human mucolipidosis and suggests that the gamma subunit functions in lysosomal hydrolase recognition.
Asunto(s)
Lisosomas/metabolismo , Mucolipidosis/genética , Transferasas (Grupos de Otros Fosfatos Sustitutos)/genética , Secuencia de Aminoácidos , Secuencia de Bases , Cromosomas Humanos Par 16 , Clonación Molecular , Femenino , Fibroblastos , Mutación del Sistema de Lectura , Ligamiento Genético , Humanos , Escala de Lod , Lisosomas/enzimología , Masculino , Datos de Secuencia Molecular , Mucolipidosis/etiología , Linaje , ARN Mensajero/metabolismo , Análisis de Secuencia , Transferasas (Grupos de Otros Fosfatos Sustitutos)/metabolismoRESUMEN
Six families with prolidase deficiency (PD) and chronic lung disease are reported, a previously unrecognized association. In one family with a classic cystic fibrosis (CF) phenotype, no evidence for CF Transmembrane Conductance Regulator (CFTR)-related mutations could be found. Chronic lung disease and CFTR-mutation negative CF may be associated with PD.
Asunto(s)
Fibrosis Quística/enzimología , Dipeptidasas/deficiencia , Enfermedades Pulmonares/enzimología , Adulto , Fibrosis Quística/genética , Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética , Humanos , Lactante , Enfermedades Pulmonares/genética , Masculino , Linaje , FenotipoRESUMEN
Some hexavalent chromium [Cr(VI)]-containing compounds are lung carcinogens. Once within cells, Cr(VI) is reduced to trivalent chromium [Cr(III)] which displays an affinity for both DNA bases and the phosphate backbone. A diverse array of genetic lesions is produced by Cr including Cr-DNA monoadducts, DNA interstrand crosslinks (ICLs), DNA-Cr-protein crosslinks (DPCs), abasic sites, DNA strand breaks and oxidized bases. Despite the large amount of information available on the genotoxicity of Cr, little is known regarding the molecular mechanisms involved in the removal of these lesions from damaged DNA. Recent work indicates that nucleotide excision repair (NER) is involved in the processing of Cr-DNA adducts in human and rodent cells. In order to better understand this process at the molecular level and begin to identify the Cr-DNA adducts processed by NER, the incision of CrCl(3) [Cr(III)]-damaged plasmid DNA was studied using a thermal-resistant UvrABC NER endonuclease from Bacillus caldotenax (Bca). Treatment of plasmid DNA with Cr(III) (as CrCl(3)) increased DNA binding as a function of dose. For example, at a Cr(III) concentration of 1 microM we observed approximately 2 Cr(III)-DNA adducts per plasmid. At this same concentration of Cr(III) we found that approximately 17% of the plasmid DNA contained ICLs ( approximately 0.2 ICLs/plasmid). When plasmid DNA treated with Cr(III) (1 microM) was incubated with Bca UvrABC we observed approximately 0.8 incisions/plasmid. The formation of endonuclease IV-sensitive abasic lesions or Fpg-sensitive oxidized DNA bases was not detected suggesting that the incision of Cr(III)-damaged plasmid DNA by UvrABC was not related to the generation of oxidized DNA damage. Taken together, our data suggest that a sub-fraction of Cr(III)-DNA adducts is recognized and processed by the prokaryotic NER machinery and that ICLs are not necessarily the sole lesions generated by Cr(III) that are substrates for NER.
Asunto(s)
Compuestos de Cromo/toxicidad , Daño del ADN , Reparación del ADN , Endodesoxirribonucleasas/metabolismo , Proteínas de Escherichia coli/metabolismo , Plásmidos/metabolismo , Bacillus/enzimología , Cromo/química , Cromo/toxicidad , Compuestos de Cromo/química , Aductos de ADN/química , Aductos de ADN/metabolismo , Plásmidos/efectos de los fármacos , Plásmidos/genéticaRESUMEN
Using the technique of premature chromosome condensation, which permits the visual inspection of interphase chromatin, we have shown previously that 28 hr after exposure to 6-thioguanine (TG) specific and drastic morphological changes in the chromosomes of Chinese hamster ovary fibroblasts in the G2 phase of the cell cycle become evident. In this paper, we demonstrate that this damage is a dose-related effect, appearing as sharp curling or "kinking" at lower TG concentrations and as unilateral chromatid damage and gross chromosome disruption at higher TG concentrations. With the use of a scoring system for quantitating the severity of this specific damage, the threshold concentrations for the appearance of unilateral chromatid damage and for loss of colony-forming ability were shown to be identical. Since the appearance of unilateral chromatid damage paralleled the appearance of TG-induced cytotoxicity in terms of time and dose, and since the severe disruption of G2 prematurely condensed chromosomes is consistent with TG-induced G2 arrest seen in this and other systems, we conclude that unilateral chromatid damage is centrally involved in the delayed cytotoxicity of TG in Chinese hamster ovary cells.
Asunto(s)
Cromátides/efectos de los fármacos , Tioguanina/toxicidad , Animales , Ciclo Celular , Supervivencia Celular/efectos de los fármacos , Cricetinae , Cricetulus , Relación Dosis-Respuesta a Droga , Femenino , Ovario/efectos de los fármacosRESUMEN
The cytotoxic action of the guanine analogue, 3-deazaguanine, was shown previously to be closely associated with deazaguanine-induced inhibition of DNA synthesis and incorporation of deazaguanine into DNA. The DNA-directed effects of the compound have been further investigated by studying the effect of deazaguanine on DNA integrity, and on the ability of pulse-labeled L1210 cells to synthesize full length DNA. Deazaguanine caused DNA single strand breaks in newly synthesized DNA but not in preformed DNA. The amount of DNA single strand breaks correlated with both deazaguanine exposure and with the amount of deazaguanine incorporated into the DNA. When cells were allowed to recover in drug-free medium for 12 or 24 h after drug exposure little effect on either the amount of DNA single strand breaks or cell viability relative to controls was observed. Deazaguanine also inhibited the ability of L1210 cells to synthesize full length DNA after pulse labeling of DNA. This effect was temporally related to the inhibition by deazaguanine of total DNA synthesis.
Asunto(s)
ADN/efectos de los fármacos , Guanina/análogos & derivados , Animales , ADN/metabolismo , Daño del ADN , Relación Dosis-Respuesta a Droga , Guanina/farmacología , Leucemia L1210/patología , Células Tumorales CultivadasRESUMEN
3-Deazaguanine, a tumor-inhibitory purine antimetabolite, is cytotoxic to L1210 leukemic cells in culture. The log percentage of viability correlated strongly (r2 = 0.986) with the product of the concentration of 3-deazaguanine, or [3-deazaguanine], and period of exposure (t) when [3-deazaguanine] was between 3 and 50 microM, and t was 12 or 24 h. We wished to relate this cytotoxicity to biochemical effects mediated by 3-deazaguanine. 3-Deazaguanine inhibited both DNA and protein synthesis, and both log DNA synthesis and log protein synthesis correlated inversely with [3-deazaguanine] X t and directly with cell viability (P less than 0.001). L1210 cells accumulated 3-deazaguanine 5'-triphosphate to a level of 1.5 nmol/10(6) cells. 3-Deazaguanine treatment had no effect on intracellular cytidine 5'-triphosphate levels, but reduced adenosine 5'-triphosphate and uridine 5'-triphosphate levels by 40% relative to control and guanosine 5'-triphosphate levels by 85% relative to control at a [3-deazaguanine] X t value at which 3-deazaguanine 5'-triphosphate accumulation was near maximal. Incorporation of 2-14C-labeled 3-deazaguanine into DNA and RNA, separated by Cs2SO4 density gradient centrifugation, was demonstrated. Incorporation into DNA was linear versus [3-deazaguanine] X t and correlated inversely with cell viability (P less than 0.001). These data suggest that 3-deazaguanine is anabolized and incorporated into DNA, and that this incorporation is related to decreased DNA synthesis and cell death. The decrease in protein synthesis and diminution of guanosine 5'-triphosphate levels following drug treatment may also contribute to the growth-inhibitory actions of 3-deazaguanine.
Asunto(s)
Antimetabolitos Antineoplásicos/metabolismo , ADN de Neoplasias/metabolismo , Guanina/análogos & derivados , Leucemia L1210/patología , ARN Neoplásico/metabolismo , Animales , Línea Celular , Supervivencia Celular/efectos de los fármacos , Guanina/metabolismo , Guanina/farmacología , Guanosina Trifosfato/análisis , Leucemia L1210/metabolismo , Proteínas de Neoplasias/biosíntesisRESUMEN
Pentobarbital depressed macromolecular synthesis in Ehrlich ascites cells in vitro, and this depression was proportional to a decrease in oxygen consumption. However, survival time of animals bearing Ehrlich ascites cells was unaffected by pentobarbital. The acute toxicity of the drug was greatly enhanced by the presence of the tumor. Sleeping time was prolonged in mice carrying the following tumors: Ehrlich ascites, Sarcoma 180 ascites, and Yancy plasma cell solid. Seven-day Ehrlich ascites tumor-bearing animals treated with pentobarbital slept about three times longer than normal mice, but both groups awoke at the same plasma levels of the unbound drug. The plasma half-life of unchanged pentobarbital was about four times as long in tumor-bearing mice as it was in controls. No qualitative difference in catabolism other than rate was detected. Renal excretion of unchanged pentobarbital in tumor-bearing animals was 50% of control animals during the first 4 hr. In tumor-bearing mice the sleeping time of the nonmetabo ble barbiturate, barbital, was identical with that in normal animals. These data suggest that the tumor affected mainly pentobarbital metabolism. Tumor-bearing mice still responded to the pharmacological challenge of phenobarbital with the apparent induction of drug metabolizing enzymes. The prolonged pentobarbital sleeping time in tumor-bearing mice required the development of some type of tumor-host relationship.
Asunto(s)
ADN de Neoplasias/metabolismo , Neoplasias Experimentales/metabolismo , Pentobarbital/farmacología , Animales , Proteínas Sanguíneas/metabolismo , Carcinoma de Ehrlich/tratamiento farmacológico , Carcinoma de Ehrlich/metabolismo , Semivida , Técnicas In Vitro , Masculino , Ratones , Ratones Endogámicos A , Ratones Endogámicos BALB C , Ratones Endogámicos ICR , Consumo de Oxígeno/efectos de los fármacos , Pentobarbital/sangre , Pentobarbital/uso terapéutico , Pentobarbital/toxicidad , Unión Proteica , Sarcoma 180/metabolismo , Sueño/efectos de los fármacosRESUMEN
In L1210 cells in culture, 3-deazaguanine (DG), a relatively new purine analog, was found to inhibit DNA and protein synthesis but not total RNA synthesis. The effect of the drug on protein synthesis was therefore further examined. Polyadenylic acid-containing RNA synthesis was not decreased by DG treatment, suggesting that the inhibiton of protein synthesis was a function of an alteration in the process of translation. DG altered the polyribosome sedimentation profile in a dose-dependent manner, increasing the numbers of monosomes and smaller polysomes and decreasing the number of larger polysomes. The nascent polypeptides in DG-treated cells were labeled with [3H]leucine, and the increased number of monosomes was not associated with a proportionate amount of [3H]leucine when compared to the polysomes. This indicated that the monosomes had not been derived directly from the breakdown of active polysomes. The shift in the polysome profile was reversed by cycloheximide, suggesting that DG profile inhibited the initiation of translation. This was confirmed by the demonstration of the inhibition of DG of the formation of the 43S preinitiation complex. The inhibition of the initiation of protein synthesis by DG may contribute to the antitumor actions of this new purine analog.
Asunto(s)
Antimetabolitos/farmacología , Guanina/análogos & derivados , Leucemia L1210/metabolismo , Iniciación de la Cadena Peptídica Traduccional/efectos de los fármacos , Animales , Guanina/farmacología , Cinética , Leucemia L1210/genética , Ratones , Biosíntesis de Proteínas/efectos de los fármacos , ARN Neoplásico/genética , Transcripción Genética/efectos de los fármacosRESUMEN
The mouse T-lymphoma (S-49) cell line is useful for individually studying RNA- and DNA-directed effects of 5-fluoropyrimidines. On the basis of their metabolic activation, biochemical effects on pyrimidine nucleotide metabolism, and biological toxicity, we hve established that incubation of S-49 cells with 5-fluorodeoxyuridine produces only DNA-directed toxicity (thymidylate synthetase inhibition), incubation with 5-fluorouracil (FUra) + thymidine only RNA-directed toxicity, and incubation with FUra alone produces both DNA- and RNA-directed toxicity. The DNA component of 5-fluoropyrimidine toxicity causes immediate growth inhibition of asynchronous S-49 cell cultures, which is self-limited within 12 hr both by the accumulation of intracellular deoxyuridine 5'-monophosphate competing for thymidylate synthetase binding and by the excretion of deoxyuridine into the cell medium which competes with 5-fluorodeoxyuridine uptake. The RNA-directed component causes growth inhibition and cell kill after a delay of 1 doubling time in asynchronous cultures. Studies with cells synchronized by centrifugal elutriation indicate that the RNA-directed FUra effects are expressed only in the G1 phase of the cell cycle and cause rapid cell lysis, while the DNA-directed component is specific to the S phase. Experiments using continuous exposure of synchronized cells to FUra alone demonstrate that the activities of the RNA- and DNA-directed components interact with each other. Specifically, DNA-directed toxicity arrests cells in S phase, preventing them from progressing into G1 where RNA-directed toxicity is expressed, which may account for the augmentation of FUra toxicity by thymidine as reported in other systems.